Lung Cancer
Volume 45 , Pages S125-S127 , August 2004

Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma

References 

  1. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: a review. J. Clin. Oncol. 1996;14:1007–1017
  2. Kindler HL. Malignant pleural mesothelioma. Curr. Treat. Options Oncol. 2000;1:313–326
  3. Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M, et al.  VEGF, VEGF type C, and their receptors play an important role in angiogenesis and lymphangiogensis in human malignant mesothelioma tumors. Br. J. Cancer. 1999;81:54–61
  4. Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, et al.  Vascular endothelial growth factor is an autocrine growth factor in malignant mesothelioma. J. Pathol. 2001;193:468–475
  5. Linder C, Linder S, Munck-Wikland E, Strander H. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res. 1998;18:2063–2068
  6. Vermeulen PB, Dirix LY, Martin M, DePooter C, Schrijvers D, Prove A, et al.  Serum levels of b-FGF and FGF in patients with metastatic solid tumors. Proc. Am. Soc. Clin. Oncol. 1996;15:90
  7. Kindler HL, Vogelzang NJ, Chien K, Stadler WM, Karczmar G, Heimann R, et al.  SU5416 in malignant mesothelioma: a University of Chicago phase II consortium study. Proc. Am. Soc. Clin. Oncol. 2001;20:341
  8. Kabbinavar FF, Wong JT, Ayala RE, Wintroub AB, Kim KJ, Ferrana N, et al.  The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice. Proc. Am. Assoc. Cancer Res. 1995;36:488
  9. Kindler HL. A double-blind placebo-controlled randomized phase II trial of gemcitabine and cisplatin with or without the VEGF inhibitor bevacizumab in patients with malignant mesothelioma. Curr. Clin. Trials Thorac. Oncol. 2001;4:2–4
  10. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, et al.  Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian, and breast cancer. Br. J. Cancer. 2000;82:812–817
  11. Govindan R, Ritter J, Suppiah R. EGFR and HER-2 overexpression in malignant mesothelioma. Proc. Am. Soc. Clin. Oncol. 2001;20:339
  12. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, et al.  Antitumor effect and potentiation of cytotoxic drug activity in human cells by ZD1839 (Iressa), an epidermal growth factor selective tyrosine kinase inhibitor. Clin. Cancer Res. 2000;6:2053–2063
  13. Langerak AW, De Laat PA, Van Der Linden-Van Beurden CA, Delahaye M, Van Der Kwast TH, Hoogsteden HC, et al.  Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. J. Pathol. 1996;178:151–160
  14. Gerwin BI, Lechner JF, Reddel RR, Roberts AB, Robbins KC, Gabrielson EW, et al.  Comparison of production of transforming growth factor-beta and platelet derived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res. 1987;47:6180–6184
  15. Mutsaers SE, McAnulty RJ, Laurent GJ, Versnel MA, Whitaker D, Papadimitriou JM. Cytokine regulation of mesothelial cell proliferation in vitro and in vivo. Eur. J. Cell Biol. 1997;72:24–29
  16. Versnel MA, Claesson-Welsh L, Hammacher A, Bouts MJ, van der Kwast TH, Eriksson A, et al.  Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha receptors. Oncogene. 1991;6:2005–2011
  17. Dorai T, Kobayashi H, Holland JF, Ohnuma T. Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme. Mol. Pharmacol. 1994;46:437–444
  18. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al.  Abl protein tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet derived growth factor receptors. J. Pharmacol. Exp. Ther. 2000;295:139–145
  19. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al.  PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor receptor-induced responses and tumor growth after oral administration. Cancer Res. 2000;60:2178–2189

PII: S0169-5002(04)00183-7

doi: 10.1016/j.lungcan.2004.04.022

Lung Cancer
Volume 45 , Pages S125-S127 , August 2004

Article Tools